title: Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.
abstract: The observational study was aimed at evaluating response, survival and toxicity of bortezomib-based, case-adjusted regimens in real-life therapy of 708 relapsed/refractory MM patients. Bortezomib was combined with anthracyclines, steroids, thalidomide, alkylators or given in monotherapy. The ORR was 67.9% for refractory and 69.9% for relapsed MM. The median PFS was 14 months and OS 57 months. Patients responding to the therapy had the probability of a 4-year OS at 67.0%. No toxicity was noted in 33.1% of patients. Severe events (grade 3/4) were reported in 35.9% of patients: neurotoxicity (16.7%), neutropenia (9.2%), thrombocytopenia (8.5%), and infections (6.5%). Bortezomib-based, case-adjusted regimens are in real-life practice effective in salvage therapy offering reliable survival with acceptable toxicity for relapsed/refractory MM patients.
authors.affiliation: Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland. Electronic address: pgsz@hematoonkologia.pl.
authors.forename: Adam
authors.initials: A
authors.lastname: Walter-Croneck
authors.affiliation: Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland.
authors.forename: Norbert
authors.initials: N
authors.lastname: Grzasko
authors.affiliation: Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland.
authors.forename: Maria
authors.initials: M
authors.lastname: Soroka-Wojtaszko
authors.affiliation: Department of Haematology, Collegium Medicum, Jagiellonian University, Cracow, Poland.
authors.forename: Artur
authors.initials: A
authors.lastname: Jurczyszyn
authors.affiliation: Department of Haematology, Oncology and Internal Medicine, Medical University of Warsaw, Poland.
authors.forename: Tigran
authors.initials: T
authors.lastname: Torosian
authors.affiliation: Department of Haematology SSM, Torun, Poland.
authors.forename: Marcin
authors.initials: M
authors.lastname: Rymko
authors.affiliation: Department of Haematology Medical University of Poznan, Poland.
authors.forename: Adam
authors.initials: A
authors.lastname: Nowicki
authors.affiliation: Department of Lymphoid Malignancies, Institute of Oncology, Warsaw, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Druzd-Sitek
authors.affiliation: Centre of Postgraduate Medical Education, Warsaw, Poland; Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Lech-Maranda
authors.affiliation: Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Madro
authors.affiliation: Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland.
authors.forename: Patrycja
authors.initials: P
authors.lastname: Zielinska
authors.affiliation: Department of Haematology Medical University of Bydgoszcz, Poland.
authors.forename: Iwona
authors.initials: I
authors.lastname: Grygoruk-Wisniowska
authors.affiliation: Department of Haematology Medical University of Bydgoszcz, Poland.
authors.forename: Danuta
authors.initials: D
authors.lastname: Blonska
authors.affiliation: Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland.
authors.forename: Lidia
authors.initials: L
authors.lastname: Usnarska-Zubkiewicz
authors.affiliation: Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland.
authors.forename: Stanislaw
authors.initials: S
authors.lastname: Potoczek
authors.affiliation: Department of Haematology Medical University of Lodz, Poland.
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Iskierka
authors.affiliation: Department of Haematology SW, Opole, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Masternak
authors.affiliation: Department of Haematology WSS, Legnica, Poland.
authors.forename: Jadwiga
authors.initials: J
authors.lastname: Holojda
authors.affiliation: Department of Haematology WSS, Legnica, Poland.
authors.forename: Dorota
authors.initials: D
authors.lastname: Dawidowska
authors.affiliation: Department of Haematology WSS, Legnica, Poland.
authors.forename: Ludmila
authors.initials: L
authors.lastname: Gawron
authors.affiliation: Department of Haematology ZSM, Chorzow, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Barchnicka
authors.affiliation: Department of Haematology, Military Institute of Medicine in Warsaw, Poland.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Olszewska-Szopa
authors.affiliation: Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland.
authors.forename: Malwina
authors.initials: M
authors.lastname: Rybicka
authors.affiliation: Department of Haematology WSS, Legnica, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Gontarska
authors.affiliation: Department of Haematology Medical University of Bydgoszcz, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Jachalska
authors.affiliation: Department of Haematology, Military Institute of Medicine in Warsaw, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Rzepecki
authors.affiliation: Department of Haematology, Military Institute of Medicine in Warsaw, Poland.
authors.forename: Edyta
authors.initials: E
authors.lastname: Subocz
authors.affiliation: Department of Haematology, Oncology and Internal Medicine, Medical University of Warsaw, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Boguradzki
authors.affiliation: Department of Haematology, Oncology and Internal Medicine, Medical University of Warsaw, Poland.
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Charlinski
authors.affiliation: Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland.
authors.forename: Monika
authors.initials: M
authors.lastname: Dzierzak-Mietla
authors.affiliation: Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Wisniewska-Piaty
authors.affiliation: Department of Haematology Medical University of Bydgoszcz, Poland.
authors.forename: Wojciech
authors.initials: W
authors.lastname: Swistek
authors.affiliation: Department of Haematology WSS, Rzeszow, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Kopacz
authors.affiliation: Department of Haematology WSS, Rzeszow, Poland.
authors.forename: Beata
authors.initials: B
authors.lastname: Blajer-Olszewska
authors.affiliation: Department of Haematology SW, Zielona Gora, Poland.
authors.forename: Alina
authors.initials: A
authors.lastname: Swiderska
authors.affiliation: Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Dmoszynska
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib
keywords: Bortezomib; Relapsed/refractory multiple myeloma; Response; Salvage therapy; Survival; Toxicity